MAPT and Alzheimer disease: Traditionally, the detection of AD neuropathological hallmarks, i.e., aggregated amyloid-β42 (Aβ42) and Tau phosphorylated at threonine 181 (pTau181), has relied on cerebrospinal fluid (CSF) analysis and nuclear medicine techniques such as positron emission tomography (PET) [4].